“…A similar study reported that EGCG administration significantly inhibited IL-6, IL-8, VEGF, and PGE2 production, decreased COX-2 expression, and inhibited NF-κB activation, with subsequent inhibition of phosphorylation of p38, JNK, and ERK in IL-1β+Aβ (25-35) -induced U373MG cells [ 219 ]. Furthermore, in microglial BV-2 cells stimulated with LPS, pretreatment with EGCG significantly inhibited the production of the proinflammatory mediator NO, decreased the release of proinflammatory cytokine IL-6 while increasing TNF-α, downregulated MIF, CCL-2, and CSF2 and upregulated IL-3, IL-11, and TNFS10, significantly downregulated mTOR, NF-κB2, STAT1, Akt3, CCL5, and SMAD3 while significantly upregulating the expression of mRNA of Ins2, Pld2, A20/TNFAIP3, and GAB1 [ 220 ]. Similarly, EGCG is associated with protection against Aβ and LPS-induced neurotoxicity in SH-SY5Y and BV-2 microglial cells through the inhibition of proinflammatory cytokines (IL-1β and IL-18), the reduction in Iba-1 over-expression, and the suppression of the co-localization of caspase-1 and Iba-1 activation as shown by immunofluorescence staining.…”